Cure8 research brief
Researchers found antisense RNA activity in gut microbes that tracks with active inflammation in IBD and with faecal calprotectin — suggesting a new microbial signal that might help understand or monitor disease activity.
Researchers studying the gut microbiome and microbial gene regulation, clinicians and lab scientists interested in IBD biomarkers and faecal-calprotectin–related monitoring, and patients curious about emerging microbiome research (research-interested patients).
This study introduces metastrand, a strand-aware metatranscriptomics plus metagenomics framework, to measure both mRNAs and antisense RNAs (asRNAs) in gut microbial communities.
The authors report that in IBD, antisense RNA programmes converge across patients during active inflammation, correlate with faecal metabolites and calprotectin, and remain stable during persistent inflammation.
They link asRNA dynamics to genomic rearrangements at insertion sequences and show similar patterns in a mouse colitis model, in vitro oxidative stress, and in gastroenteritis patients. The work suggests asRNAs are a previously underappreciated layer of microbial adaptation and may serve as biomarkers of intestinal inflammatory activity.
The study uses observational human cohorts plus experimental models; the abstract indicates correlations with calprotectin and metabolites rather than validated clinical assays. This brief is grounded in the article abstract published in Nature Microbiology (structured content depth: abstract).
Cure8 has not reviewed the full paper; details such as cohort size, statistical strength, or clinical performance of proposed biomarkers are not available here. If you’re interpreting this for personal care: this research is exploratory and does not change clinical management. Speak with your care team about any testing or biomarker questions.
Structured content depth is abstract from a Nature Microbiology article; Cure8 did not review the full paper. The findings reported are correlative in human samples and supported by model systems; they do not represent a validated clinical test or actionable medical recommendation.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Competing interests: R.J.X. is a co-founder of Convergence Bio, scientific advisory board member at Nestlé and Magnet BioMedicine and board director at MoonLake Immunotherapeutics; these organizations had no role in this study. D.R.P. is employed at Novonesis A/S. All other authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
Researchers used genetics, microbiome, metabolism, and immune profiling together to nominate biological pathways and a four-gene signature that might help diagnose or explain ulcerative colitis. If validated later, these...
